These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 29868006)

  • 21. Cationic solid-lipid nanoparticles are as efficient as electroporation in DNA vaccination against visceral leishmaniasis in mice.
    Saljoughian N; Zahedifard F; Doroud D; Doustdari F; Vasei M; Papadopoulou B; Rafati S
    Parasite Immunol; 2013 Dec; 35(12):397-408. PubMed ID: 23710803
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.
    Melby PC; Yang J; Zhao W; Perez LE; Cheng J
    Infect Immun; 2001 Aug; 69(8):4719-25. PubMed ID: 11447143
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Making an anti-amastigote vaccine for visceral leishmaniasis: rational, update and perspectives.
    Fernandes AP; Coelho EA; Machado-Coelho GL; Grimaldi G; Gazzinelli RT
    Curr Opin Microbiol; 2012 Aug; 15(4):476-85. PubMed ID: 22698479
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Leishmania Vaccines: the Current Situation with Its Promising Aspect for the Future.
    Dinc R
    Korean J Parasitol; 2022 Dec; 60(6):379-391. PubMed ID: 36588414
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vaccination with Leishmania histone H1-pulsed dendritic cells confers protection in murine visceral leishmaniasis.
    Agallou M; Smirlis D; Soteriadou KP; Karagouni E
    Vaccine; 2012 Jul; 30(34):5086-93. PubMed ID: 22704924
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DNA vaccine against visceral leishmaniasis: a promising approach for prevention and control.
    Kumar A; Samant M
    Parasite Immunol; 2016 May; 38(5):273-81. PubMed ID: 27009772
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vaccine candidates against leishmania under current research.
    Iborra S; Solana JC; Requena JM; Soto M
    Expert Rev Vaccines; 2018 Apr; 17(4):323-334. PubMed ID: 29589966
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Canine Leishmania vaccines: still a long way to go.
    Gradoni L
    Vet Parasitol; 2015 Feb; 208(1-2):94-100. PubMed ID: 25620293
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Leishmania donovani serine protease encapsulated in liposome elicits protective immunity in experimental visceral leishmaniasis.
    Das P; Paik D; Naskar K; Chakraborti T
    Microbes Infect; 2018 Jan; 20(1):37-47. PubMed ID: 28970116
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vaccines for leishmaniasis: from proteome to vaccine candidates.
    Schroeder J; Aebischer T
    Hum Vaccin; 2011; 7 Suppl():10-5. PubMed ID: 21245661
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vaccinomics strategy to concoct a promising subunit vaccine for visceral leishmaniasis targeting sandfly and leishmania antigens.
    Ojha R; Pandey RK; Prajapati VK
    Int J Biol Macromol; 2020 Aug; 156():548-557. PubMed ID: 32311400
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vaccines for visceral leishmaniasis: A review.
    Jain K; Jain NK
    J Immunol Methods; 2015 Jul; 422():1-12. PubMed ID: 25858230
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cysteine proteinase type III is protective against Leishmania infantum infection in BALB/c mice and highly antigenic in visceral leishmaniasis individuals.
    Khoshgoo N; Zahedifard F; Azizi H; Taslimi Y; Alonso MJ; Rafati S
    Vaccine; 2008 Oct; 26(46):5822-9. PubMed ID: 18804512
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vaccines for leishmaniasis in the fore coming 25 years.
    Palatnik-de-Sousa CB
    Vaccine; 2008 Mar; 26(14):1709-24. PubMed ID: 18295939
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Not All Antigens Are Created Equally: Progress, Challenges, and Lessons Associated with Developing a Vaccine for Leishmaniasis.
    Duthie MS; Reed SG
    Clin Vaccine Immunol; 2017 Jul; 24(7):. PubMed ID: 28515135
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vaccination of dogs with six different candidate leishmaniasis vaccines composed of a chimerical recombinant protein containing ribosomal and histone protein epitopes in combination with different adjuvants.
    Poot J; Janssen LH; van Kasteren-Westerneng TJ; van der Heijden-Liefkens KH; Schijns VE; Heckeroth A
    Vaccine; 2009 Jul; 27(33):4439-46. PubMed ID: 19500553
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of immune responses and protection induced by A2 and nucleoside hydrolase (NH) DNA vaccines against Leishmania chagasi and Leishmania amazonensis experimental infections.
    Zanin FH; Coelho EA; Tavares CA; Marques-da-Silva EA; Silva Costa MM; Rezende SA; Gazzinelli RT; Fernandes AP
    Microbes Infect; 2007 Jul; 9(9):1070-7. PubMed ID: 17644455
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Translating Observations From Leishmanization Into Non-Living Vaccines: The Potential of Dendritic Cell-Based Vaccination Strategies Against
    Seyed N; Peters NC; Rafati S
    Front Immunol; 2018; 9():1227. PubMed ID: 29922288
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular, biochemical characterization and assessment of immunogenic potential of cofactor-independent phosphoglycerate mutase against Leishmania donovani: a step towards exploring novel vaccine candidate.
    Tandon R; Chandra S; Baharia RK; Misra P; Das S; Rawat K; Siddiqi MI; Sundar S; Dube A
    Parasitology; 2018 Apr; 145(4):508-526. PubMed ID: 28691653
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vaccines for the leishmaniases: proposals for a research agenda.
    ; Costa CH; Peters NC; Maruyama SR; de Brito EC; Santos IK
    PLoS Negl Trop Dis; 2011 Mar; 5(3):e943. PubMed ID: 21468307
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.